Tinte Itinteang

Tinte Itinteang

Auto-generated profile, based on publicly available information

Tinte Itinteang

Gillies McIndoe Research Institute, Wellington 6242, New Zealand

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2016 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
ABAmy Bradshaw
Amy Bradshaw
AWAgadha Wickremsekera
Agadha Wickremsekera
STSwee T Tan
Swee T Tan
LPLifeng Peng
Lifeng Peng
PDPaul F. Davis
Paul F. Davis
TITinte Itinteang
Tinte Itinteang
Glioblastoma multiforme (GBM), an aggressive tumor that typically exhibits treatment failure with high mortality rates, is associated with the presence of cancer stem cells (CSCs) within the tumor. CSCs possess the ability for perpetual self-renewal and proliferation, producing downstream progenitor cells that drive tumor growth. Studies of many cancer types have identified CSCs using specific markers, but it is still unclear as to where in the stem cell hierarchy these markers fall. This is compounded further by the presence of multiple GBM and glioblastoma cancer stem cell subtypes, making investigation and establishment of a universal treatment difficult. This review examines the current knowledge on the CSC markers SALL4, OCT-4, SOX2, STAT3, NANOG, c-Myc, KLF4, CD133, CD44, nestin, and glial fibrillary acidic protein, specifically focusing on their use and validity in GBM research and how they may be utilized for investigations into GBM’s cancer biology.

1 June 2011 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
TITinte Itinteang
Tinte Itinteang
HBHelen D. Brasch
Helen D. Brasch
STSwee T. Tan
Swee T. Tan
DDDarren J. Day
Darren J. Day

2 June 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
RBRanui Baillie
Ranui Baillie
STSwee T. Tan
Swee T. Tan
TITinte Itinteang
Tinte Itinteang
Cancer stem cells (CSCs) have been identified in oral cavity squamous cell carcinoma (OCSCC). CSCs possess the ability for perpetual self-renewal and proliferation, producing downstream progenitor cells and cancer cells that drive tumor growth. Studies of many cancer types including OCSCC have identified CSCs using specific markers, but it is still unclear as to where in the stem cell hierarchy these markers fall. This is compounded further by the presence of multiple CSC subtypes within OCSCC, making investigation reliant on the use of multiple markers. This review examines the current knowledge in CSC markers OCT4, SOX2, NANOG, ALDH1, pSTAT3, CD44, CD24, CD133, MUSASHI-1, specifically focusing on their use and validity in OCSCC CSC research and how they may be organized into the CSC hierarchy. OCSCC CSCs also express components of the renin-angiotensin system (RAS), which suggests CSCs may be novel therapeutic targets by modulation of the RAS using existing medications.

1 March 2011 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
STSwee T. Tan
Swee T. Tan
TITinte Itinteang
Tinte Itinteang
PLPhilip Leadbitter
Philip Leadbitter

25 September 2014 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
TITinte Itinteang
Tinte Itinteang
AWAaron H. J. Withers
Aaron H. J. Withers
PDPaul F. Davis
Paul F. Davis
STSwee T Tan
Swee T Tan
Infantile hemangioma (IH), the most common tumor of infancy, is characterized by an initial proliferation during infancy followed by spontaneous involution over the next 5–10 years, often leaving a fibro-fatty residuum. IH is traditionally considered a tumor of the microvasculature. However, recent data show the critical role of stem cells in the biology of IH with emerging evidence suggesting an embryonic developmental anomaly due to aberrant proliferation and differentiation of a hemogenic endothelium with a neural crest phenotype that possesses the capacity for endothelial, hematopoietic, mesenchymal, and neuronal differentiation. Current evidence suggests a putative placental chorionic mesenchymal core cell embolic origin of IH during the first trimester. This review outlines the emerging role of stem cells and their interplay with the cytokine niche that promotes a post-natal environment conducive for vasculogenesis involving VEGFR-2 and its ligand VEGF-A and the IGF-2 ligand in promoting cellular proliferation, and the TRAIL-OPG anti-apoptotic pathway in preventing cellular apoptosis in IH. The discovery of the role of the renin–angiotensin system in the biology of IH provides a plausible explanation for the programed biologic behavior and the β-blocker-induced accelerated involution of this enigmatic condition. This crucially involves the vasoactive peptide, angiotensin II, that promotes cellular proliferation in IH predominantly via its action on the ATIIR2 isoform. The role of the RAS in the biology of IH is further supported by the effect of captopril, an ACE inhibitor, in inducing accelerated involution of IH. The discovery of the critical role of RAS in IH represents a novel and fascinating paradigm shift in the understanding of human development, IH, and other tumors in general.

3 March 2016 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
SJSophie de Jong
Sophie de Jong
TITinte Itinteang
Tinte Itinteang
AWAaron H. J. Withers
Aaron H. J. Withers
PDPaul F. Davis
Paul F. Davis
STSwee T Tan
Swee T Tan